Board-certified in pediatric cardiology and adult congenital heart disease, Erika Berman Rosenzweig, M.D., is an internationally prominent physician in her field, with a reputation as an outstanding clinician, teacher, and researcher. An expert in the field of pulmonary hypertension, Dr. Rosenzweig joined New York Medical College as chair and Westchester Medical Center as director of the Department of Pediatrics and as the William Russell McCurdy Physician-in-Chief at WMCHealth’s Maria Fareri Children’s Hospital in 2024. She previously served as vice chair for clinical/translational research in the Department of Pediatrics and director of the Adult and Pediatric Pulmonary Hypertension Comprehensive Care Center at Columbia University Medical Center/NewYork-Presbyterian Hospital.
Education
- Fellowship, Pediatric Cardiology and Pulmonary Hypertension, Columbia University
- Residency, Pediatrics, Columbia University
- M.D., Mount Sinai School of Medicine
Research
Dr. Rosenzweig’s research has been widely published and she has served as site principal investigator on more than 50 clinical drug trials, devoting remarkable efforts toward clinical research on the study of novel treatments of pulmonary arterial hypertension, as well as novel approaches to mechanical support for patients with end-stage pulmonary hypertension. She currently serves as director of the Pediatric Pulmonary Hypertension Network of North America, as a Pediatric Task Force advisor for the 2024 World Symposium on pulmonary hypertension, and as immediate past chair of the Pulmonary Vascular Disease Interdisciplinary Network Steering Committee for the International Society for Heart and Lung Transplantation.
Publications
- Reddy YNV, Frantz RP, Miranda WR, et. al. "Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension." The European respiratory journal, (), (2026) . pii: 2501871. doi: 10.1183/13993003.01871-2025
- Reddy YNV, Frantz RP, Miranda WR, et. al. "Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension." Circulation, (), (2026) . doi: 10.1161/CIRCULATIONAHA.125.077606
- Rhee KE, Thaweethai T, Pant DB, et. al. "Social Determinants of Health and Pediatric Long COVID in the US." JAMA pediatrics, (), (2026) . doi: 10.1001/jamapediatrics.2025.5485
- Reddy YNV, Frantz RP, Hemnes AR, et. al. "Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension." Circulation. Heart failure, 19(1), (2026) e013591. doi: 10.1161/CIRCHEARTFAILURE.125.013591
- Kolaitis NA, Sahay S, Rosenzweig EB, et. al. "American Lung Association Pulmonary Hypertension Roundtable: Executive Summary." Pulmonary circulation, 15(4), (2025) e70200. doi: 10.1002/pul2.70200
- Austin ED, Mullen MP, Avitabile CM, et. al. "Pulmonary Hemodynamics and Long-Term Outcomes in Children with Pulmonary Hypertension-Associated Bronchopulmonary Dysplasia." The Journal of pediatrics, 289(), (2026) 114869. doi: 10.1016/j.jpeds.2025.114869
- Gross RS, Thaweethai T, Salisbury AL, et. al. "Characterizing Long COVID Symptoms During Early Childhood." JAMA pediatrics, 179(7), (2025) 781-92. doi: 10.1001/jamapediatrics.2025.1066
Memberships and Affiliations
Dr. Rosenzweig has been an active member of the Pulmonary Hypertension Association (PHA), currently serving as a distinguished faculty advisor to the Scientific Leadership Council. She previously served on the PHA Board of Trustees, as chair of the Scientific Leadership Council, and as editor-in-chief of the medical journal Advances in Pulmonary Hypertension.
